As shown in Fig. 3a, patients with an anti-TERT Th1 response had significantly lower rates of circulating PD-1+/TIM-3+ CD4+ T cells than non-responders NSCLC patients. The gene discussed is CD4; the disease is non-small cell lung carcinoma.